Inotrem Signs a Worldwide License agreement with Roche Diagnostic for CDx Test in Septic Shock

 Inotrem Signs a Worldwide License agreement with Roche Diagnostic for CDx Test in Septic Shock

Inotrem, Signs, Worldwide, License Agreement, Roche Diagnostic, CDx Test, Septic Shock

Shots:

  • Inotrem enters into a global licensing agreement with Roche Diagnostics to commercialize mechanism-based CDx test utilizing a soluble plasma protein (sTREM-1)
  • The collaboration leads towards the enhancement of Inotrem’s approach targeting TREM-1 pathway and allows it to focus on the development of a nangibotide-based septic shock treatment
  • LR12 (nangibotide) is the first-in-class TREM-1 inhibitor with the potential to treat septic shock and MI. Inotrem has initiated its P-IIb ASTONISH study with a focus to demonstrate the efficacy of nangibotide, and bring clinically relevant proof of clinical activity in patients with septic shock

Click here ­to­ read full press release/ article | Ref: Inotrem | Image: Inotrem

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post